GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.29
-0.05 (-3.73%)
▼
5d:
-9.15%
30d:
+1.57%
90d:
-16.23%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 7.9/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GERN is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: GERN is fairly valued with market pricing in 1.0% annual growth. Fine to hold or accumulate slowly on dips.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.29, which is considered oversold relative to its 30-day fair value range of $1.33 to $1.48. The stock's valuation (Forward PE: 21.5) is in line with its historical norms (20.9). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. Immediate support is located at $1.22, while resistance sits at $1.53. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.25 (+229.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GERN is in a downtrend. Immediate support is located at $1.22, while resistance sits at $1.53. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.25 (+229.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.33 -
$1.48
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 229.5% below Wall St target ($4.25)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -9.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.33 -
$1.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.22
Resistance Level
$1.53
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.50
Wall Street Target
$4.25
(+229.5%)
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Valuation Premium vs History
+1.0% premium
PE vs Historical
21.5 vs 20.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$1.30
(+1%)
2-Year Target
$1.32
(+2%)
3-Year Target
$1.33
(+3%)
3-Yr Target (if PE normalizes)
(PE: 22→21)
PE COMPRESSION
$1.29
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 03, 2026 1:50 AM ET
Data refreshes hourly during market hours. Next update: 2:50 AM
Data refreshes hourly during market hours. Next update: 2:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
